Technology | April 10, 2009

BioReference Labs Develops NextGen Sequencing for Dilated Cardiomyopathy Testing

April 20, 2009 - BioReference Laboratories Inc. is now offering next- generation sequencing testing for Dilated Cardiomyopathy (DCM) through its GeneDx laboratory.

GeneDx is reportedly the first commercial laboratory in the country, and possibly the world, to offer clinical testing based on next-generation sequencing, full genome sequencing provided through high-speed, high throughput computer-based analysis. GeneDx has designed software said to provide focused, multi-gene diagnostic analysis of complex cases spanning multiple genes. GeneDx first pioneered the use of this platform with its test for Hypertrophic Cardiomyopathy (HCM), which it began offering in September 2008.

It is estimated that 20 to 40 percent of patients diagnosed with idiopathic cardiomyopathy may have a genetic etiology to their condition. The new GeneDx DCM test will allow cardiologists to identify patients with a genetic basis to their dilated cardiac condition. GeneDx provides testing for more than 250 rare disease conditions based on over 200 genes utilizing traditional DNA sequencing.

For more information: www.bioreference.com

Related Content

The Corus CAD genetic test is a simple, noninvasive blood test that is clinically available for the assessment of obstructive coronary artery disease.

The Corus CAD gene expression test is a simple, noninvasive blood test that is available to assess a patient’s current likelihood of having obstructive coronary artery disease (CAD).

 

Feature | Genetic Testing | December 13, 2017 | Andrew Waxler, M.D., FACC
The diagnosis and management of cardiovascular disease has long followed a familiar approach.
genetic testing, sudden cardiac death of teen, Mayo Clinic Proceedings
News | Genetic Testing | November 09, 2016
The recent, sudden death of a 13-year-old boy resulted in more than 20 relatives being incorrectly diagnosed as having...
News | Genetic Testing | July 26, 2016
July 26, 2016 — A new study has identified a genetic error that weakens the aorta, placing patients with this and sim
Feature | Genetic Testing | December 22, 2015 | Kevin P. Greene, M.D.
Statins are lifesaving medications — they have been shown to greatly reduce heart attack and other related events by
Invitae Corp., cardiovascular test panels, genetic testing, expands offerings
Technology | Genetic Testing | October 08, 2015
Invitae Corp., a genetic information company, announced the expansion of its cardiology offering, including more than...
genomic testing, NGS, FDA, Precision Medicine Initiative, PMI, workshops
Feature | Genetic Testing | September 21, 2015
The U.S. Food and Drug Administration (FDA) will hold a pair of public workshops in November to explain ongoing efforts...
Overlay Init